MiMedx - Stock Price History | MDXG

Historical daily share price chart and data for MiMedx since 2021 adjusted for splits. The latest closing stock price for MiMedx as of October 22, 2021 is 7.03.
  • The all-time high MiMedx stock closing price was 17.96 on January 29, 2018.
  • The MiMedx 52-week high stock price is 15.99, which is 127.5% above the current share price.
  • The MiMedx 52-week low stock price is 3.66, which is 47.9% below the current share price.
  • The average MiMedx stock price for the last 52 weeks is 9.60.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
MiMedx Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 4.2700 3.6600 10.1700 3.4300 9.0800 148.09%
2019 3.6600 3.6600 3.6600 3.6600 3.6600 0.00%
2018 6.9081 12.9800 17.9600 3.2200 3.6600 -70.98%
2017 12.2176 8.7600 17.3400 7.6800 12.6100 42.33%
2016 8.2453 8.9600 9.9900 6.6600 8.8600 -5.44%
2015 9.7193 9.7400 12.9700 7.2800 9.3700 -18.73%
2014 7.5215 8.4500 11.8700 5.0900 11.5300 31.92%
2013 5.7006 3.9500 8.7400 3.8490 8.7400 127.60%
2012 2.0436 1.2500 3.8500 1.0300 3.8400 239.82%
2011 1.1363 1.3500 1.4200 0.7600 1.1300 -16.30%
2010 1.1873 0.7500 1.7500 0.7500 1.3500 84.93%
2009 0.8279 4.4000 4.4000 0.4000 0.7300 -83.41%
2008 4.8732 4.6296 6.4815 2.6000 4.4000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.787B $0.248B
MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. `Innovations in Regenerative Biomaterials` is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76